• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • EGFR-Mutant NSCLC
Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances
Posted innews Oncology Respiratory

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

Posted by By MedXY 10/25/2025
This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.
Read More
High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial
Posted inClinical Updates Oncology Specialties

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

Posted by By MedXY 09/11/2025
The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeutic potential.
Read More
  • Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults
  • Early Diagnosis of Postpartum Haemorrhage: Insights from the E-MOTIVE Trial in Africa
  • Oral Manifestations of Lamellar Ichthyosis: A Case Report of Two Siblings
  • Optimizing Scar Healing Post-Dermatologic Surgery: A Comparative Look at Hydrocolloid Dressings and Petroleum Ointments
  • Efficacy and Challenges of Targeted Indoor Residual Spraying for Aedes-Borne Virus Prevention: Insights from a Cluster-Randomized Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk clinical trial COPD depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation long-term outcomes mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health targeted therapy treatment type 2 diabetes weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in